Amelia Ruffatti1, Alessia Cerutti2, Marta Tonello3, Maria Favaro3, Teresa Del Ross3, Antonia Calligaro3, Chiara Grava4, Margherita Zen3, Ariela Hoxha5, Giovanni Di Salvo2. 1. Department of Medicine, DIMED, University of Padua, Padua, Italy. amelia.ruffatti@unipd.it. 2. Department of Women's and Children's Health, Pediatric Cardiology Unit, University of Padua, Padua, Italy. 3. Department of Medicine, DIMED, Rheumatology Unit, University of Padua, Padua, Italy. 4. Department of Medicine, Rheumatology Unit, S. Martino Hospital, Belluno, Italy. 5. Department of Medicine, DIMED, General Internal Medicine Unit, University of Padua, Padua, Italy.
Abstract
OBJECTIVE: The short and long-term outcomes of children with anti-Ro/La-related congenital heart block treated with a combined maternal-neonatal therapy protocol were compared with those of controls treated with other therapies. STUDY DESIGN: Sixteen mothers were treated during pregnancy with a therapy consisting of daily oral fluorinated steroids, weekly plasma exchange and fortnightly intravenous immunoglobulins and their neonates with intravenous immunoglobulins (study group); 19 mothers were treated with fluorinated steroids alone or associated to intravenous immunoglobulins or plasma exchange (control group). RESULT: The combined-therapy children showed a significantly lower progression rate from 2nd to 3rd degree block at birth, a significant increase in heart rate at birth and a significantly lower number of pacemaker implants during post-natal follow-up with respect to those treated with the other therapies. CONCLUSION: The combined therapy produced better short and long term outcomes with respect to the other therapies studied.
OBJECTIVE: The short and long-term outcomes of children with anti-Ro/La-related congenital heart block treated with a combined maternal-neonatal therapy protocol were compared with those of controls treated with other therapies. STUDY DESIGN: Sixteen mothers were treated during pregnancy with a therapy consisting of daily oral fluorinated steroids, weekly plasma exchange and fortnightly intravenous immunoglobulins and their neonates with intravenous immunoglobulins (study group); 19 mothers were treated with fluorinated steroids alone or associated to intravenous immunoglobulins or plasma exchange (control group). RESULT: The combined-therapy children showed a significantly lower progression rate from 2nd to 3rd degree block at birth, a significant increase in heart rate at birth and a significantly lower number of pacemaker implants during post-natal follow-up with respect to those treated with the other therapies. CONCLUSION: The combined therapy produced better short and long term outcomes with respect to the other therapies studied.
Authors: Johannes Mofors; Håkan Eliasson; Aurelie Ambrosi; Stina Salomonsson; Amanda Skog; Michael Fored; Anders Ekbom; Gunnar Bergman; Sven-Erik Sonesson; Marie Wahren-Herlenius Journal: Ann Rheum Dis Date: 2019-02-26 Impact factor: 19.103
Authors: Håkan Eliasson; Sven-Erik Sonesson; Gurleen Sharland; Fredrik Granath; John M Simpson; Julene S Carvalho; Hana Jicinska; Viktor Tomek; Joanna Dangel; Paulo Zielinsky; Maria Respondek-Liberska; Matthias W Freund; Mats Mellander; Joaquim Bartrons; Helena M Gardiner Journal: Circulation Date: 2011-10-10 Impact factor: 29.690
Authors: Nathalie Morel; Kateri Lévesque; Alice Maltret; Gabriel Baron; Mohamed Hamidou; Pauline Orquevaux; Jean-Charles Piette; François Barriere; Jérôme Le Bidois; Laurent Fermont; Olivier Fain; Arnaud Theulin; François Sassolas; Quentin Hauet; Gaëlle Guettrot-Imbert; Sophie Georgin-Lavialle; Christophe Deligny; Eric Hachulla; Luc Mouthon; Claire Le Jeunne; Philippe Ravaud; Delphine Le Mercier; Bénédicte Romefort; Elisabeth Villain; Damien Bonnet; Nathalie Costedoat-Chalumeau Journal: Int J Cardiol Date: 2017-08-07 Impact factor: 4.164
Authors: Sara M Trucco; Edgar Jaeggi; Bettina Cuneo; Anita J Moon-Grady; Earl Silverman; Norman Silverman; Lisa K Hornberger Journal: J Am Coll Cardiol Date: 2011-02-08 Impact factor: 24.094
Authors: Pilar Brito-Zerón; Peter M Izmirly; Manuel Ramos-Casals; Jill P Buyon; Munther A Khamashta Journal: Nat Rev Rheumatol Date: 2015-03-24 Impact factor: 20.543
Authors: M Kuleva; J Le Bidois; A Decaudin; E Villain; N Costedoat-Chalumeau; D Lemercier; Y Dumez; Y Ville; D Bonnet; L J Salomon Journal: Prenat Diagn Date: 2015-02-26 Impact factor: 3.050
Authors: Deborah M Friedman; Mimi Y Kim; Joshua A Copel; Carolina Llanos; Claudine Davis; Jill P Buyon Journal: Am J Cardiol Date: 2009-03-04 Impact factor: 2.778